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Abstract: The Aggregatibacter actinomycetemcomitans cytolethal distending toxin (Cdt) induces
lymphocytes to undergo cell-cycle arrest and apoptosis; toxicity is dependent upon the active Cdt subunit,
CdtB. We now demonstrate that p21CIP1/WAF1 is critical to Cdt-induced apoptosis. Cdt induces increases in
the levels of p21CIP1/WAF1 in lymphoid cell lines, Jurkat and MyLa, and in primary human lymphocytes.
These increases were dependent upon CdtB’s ability to function as a phosphatidylinositol (PI)
3,4,5-triphosphate (PIP3) phosphatase. It is noteworthy that Cdt-induced increases in the levels of
p21CIP1/WAF1 were accompanied by a significant decline in the levels of phosphorylated p21CIP1/WAF1.
The significance of Cdt-induced p21CIP1/WAF1 increase was assessed by preventing these changes
with a two-pronged approach; pre-incubation with the novel p21CIP1/WAF1 inhibitor, UC2288,
and development of a p21CIP1/WAF1-deficient cell line (Jurkatp21−) using clustered regularly interspaced
short palindromic repeats (CRISPR)/cas9 gene editing. UC2288 blocked toxin-induced increases
in p21CIP1/WAF1, and JurkatWT cells treated with this inhibitor exhibited reduced susceptibility
to Cdt-induced apoptosis. Likewise, Jurkatp21− cells failed to undergo toxin-induced apoptosis.
The linkage between Cdt, p21CIP1/WAF1, and apoptosis was further established by demonstrating that
Cdt-induced increases in levels of the pro-apoptotic proteins Bid, Bax, and Bak were dependent upon
p21CIP1/WAF1 as these changes were not observed in Jurkatp21− cells. Finally, we determined that the
p21CIP1/WAF1 increases were dependent upon toxin-induced increases in the level and activity of the
chaperone heat shock protein (HSP) 90. We propose that p21CIP1/WAF1 plays a key pro-apoptotic role
in mediating Cdt-induced toxicity.
Keywords: Aggregatibacter actinomycetemcomitans; cytolethal distending toxin; lymphocytes;
apoptosis; virulence
1. Introduction
The cytolethal distending toxin (Cdt) is a putative virulence factor that is produced by a wide range
of human pathogens capable of colonizing mucocutaneous tissue, resulting in disease characterized by
persistent infection and inflammation (reviewed in References [1,2]). In general, Cdts are heterotrimeric
complexes encoded by an operon of three genes designated cdtA, cdtB, and cdtC which encode
three polypeptides: CdtA, CdtB, and CdtC with molecular masses of 23–30, 28–32, and 19–20 kDa,
respectively [3–13]. Analyses of subunit structure and function indicate that the heterotrimeric
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holotoxin functions as an AB2 toxin; the cell binding unit (B) is responsible for toxin association with
the cell surface and is composed of subunits CdtA and CdtC. These subunits deliver the active subunit
(A), CdtB, to intracellular compartments. Cdt binding and CdtB internalization are both dependent
upon toxin binding to target cell cholesterol in the context of cholesterol-rich membrane microdomains
(reviewed in Reference [14]).
Cdt B internalization leads to irreversible cell-cycle arrest and eventually apoptotic cell death. These
toxic effects were originally attributable to CdtB’s ability to function as a DNase, thereby causing DNA
damage which in turn leads to G2/M arrest and death [9,15–23]. Over the past several years, our studies
suggested an alternative paradigm to account for Aggregatibacter actinomycetemcomitans Cdt-mediated
toxicity which is based upon a novel molecular mode of action for CdtB. In this regard, we demonstrated
that, in addition to exhibiting DNase activity, CdtB is a potent lipid phosphatase capable of converting
the signaling lipid phosphatidylinositol (PI)-3,4,5-triphosphate (PIP3) to PI-3,4-diphosphate [24–28].
Moreover, our investigations demonstrated that the ability of CdtB to function as a PIP3 phosphatase
enables this toxin subunit to intoxicate cells via blockade of the PI-3K signaling pathway. Indeed, we
demonstrated that the toxic effects of Cdt on lymphocytes, macrophages, and mast cells results in
PI-3K signaling blockade characterized by decreases in PIP3, leading to concomitant reductions in the
phosphorylation status of downstream targets: Akt and GSK3β. Additionally, we demonstrated that
the induction of both G2/M arrest and apoptosis is dependent upon CdtB-mediated PI-3K blockade.
In order to more accurately define the molecular mechanisms that link CdtB-mediated PI-3K
blockade with G2/M arrest and apoptosis, we investigated the role of the cyclin-dependent kinase
inhibitor known as CDK-interacting protein 1 (Cip1) and wild-type p53-activated fragment 1 (WAF1)
(p21CIP1/WAF1). P21CIP1/WAF1 was originally identified as a negative regulator of the cell cycle, as well as
a tumor suppressor. However, recent studies demonstrated additional functions for p21CIP1/WAF1 that
are associated with regulation of a number of cellular processes including cell differentiation, migration,
senescence, and apoptosis [29–33]. Thus, it is not surprising that several investigators demonstrated
an association between p21CIP1/WAF1 expression and exposure to Cdt [16,34–37]. It should be noted,
however, that these studies did not provide any information as to whether the p21CIP1/WAF1 levels
were mechanistically linked to and/or required for Cdt toxicity. In this study, we investigated the
relationship between lymphocyte exposure to A. actinomycetemcomitans Cdt, altered p21CIP1/WAF1 levels,
and induction of toxicity. We now report that Cdt-treated human lymphocytes exhibit dose-dependent
increases in levels of p21CIP1/WAF1 and the chaperone HSP90 within 4–16 h of exposure to the toxin.
To study the biologic consequence of these increases, we employed a two-pronged approach to modify
the ability of Cdt to alter expression of p21CIP1/WAF1: gene editing and pharmacologic intervention.
Additionally, these interventions were assessed for their ability to alter cell susceptibility to Cdt toxicity.
Our results indicate a requisite role for p21CIP1/WAF1 in Cdt-induced apoptosis.
2. Results
2.1. Cdt Induces Elevations in Lymphocyte Levels of p21CIP1/WAF1
Cdt derived from A. actinomycetemcomitans, Haemophilus ducreyi, and Helicobacter hepaticus
were shown to induce increases in p21CIP1/WAF1 within 24–48 h in several cell lines including
fibroblasts, lymphocytes, enterocytes, and hepatocytes [16,34–38]. Likewise, we now demonstrate
that A. actinomyetemcomitans Cdt induces increases in p21CIP1/WAF1 levels in Jurkat cells in a time- and
dose-dependent manner. Jurkat cells were treated with varying amounts of Cdt (0–400 pg/mL) for
4, 8, and 16 h and then analyzed by Western blot to assess total p21CIP1/WAF1 levels (Figure 1A,B).
Analysis indicates that a small, but consistent, increase in p21CIP1/WAF1 was detected within 4 h in
cells exposed to the highest concentration of Cdt (400 pg/mL). Following an 8-h exposure, significant
increases of nine- and 18-fold were observed in cells exposed to 100 and 400 pg/mL Cdt, respectively.
After a 16-h exposure, the relative levels of p21CIP1/WAF1 remained elevated; cells treated with 25, 100,
and 400 pg/mL Cdt exhibited three-, six-, and seven-fold increases, respectively.
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mean (SEM) of four experiments. Panel (C) shows the relative levels of pp21CIP1/WAF1 in cells treated 
with 50 pg/mL Cdt or 0.5 μM GSK690693 for 16 h expressed as a percentage observed in control 
(medium only) cells. A representative blot is shown along with compiled results from three 
experiments: results are expressed as the percentage (mean ± SEM) of pp21CIP1/WAF1 observed in control 
cells; * indicates statistical significance (p < 0.05) when compared to untreated cells. 
To verify that the effects of Cdt on p21CIP1/WAF1 levels were not unique to the Jurkat cell line, the 
cutaneous T-cell lymphoma line, MyLa, was also assessed for altered p21CIP1/WAF1 levels when exposed 
to the same doses of Cdt. As shown in Figure 2A,B, MyLa cells treated with 0–400 pg/mL Cdt for 16 
h exhibited significant increases in p21CIP1/WAF1levels: 4.5- (100 pg/mL Cdt) and 5.7-fold (400 pg/mL 
Cdt) over control levels. In addition to lymphoid cell lines, p21CIP1/WAF1 levels were assessed in primary 
human lymphocytes (HPBMCs). As shown in Figure 2A,B, exposure to 25 pg/mL Cdt resulted in a 
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sho s the results from ultiple blots which were analyzed by digital densitometry; the value of relative
intensity obtained from digital densitometry is presented as the mean ± standard error of the mean
(SEM) of four experiments. Panel (C) shows the relative levels of pp21CIP1/WAF1 in cells treated with
50 pg/mL Cdt or 0.5 µM GSK690693 for 16 h expressed as a percentage observed in control (medium
only) cells. A representative blot is shown along with compiled results from three experiments: results
are expressed as the percentage (mean ± SEM) of pp21CIP1/WAF1 observed in control cells; * indicates
statistical significance (p < 0.05) when compared to untreated cells.
To verify that the effects of Cdt on p21CIP1/WAF1 levels were not unique to the Jurkat cell line,
the cutaneous T-cell lymphoma line, MyLa, was also assessed for altered p21CIP1/WAF1 levels when
exposed to the same doses of Cdt. As shown in Figure 2A,B, MyLa cells treated with 0–400 pg/mL
Cdt for 16 h exhibited significant increases in p21CIP1/WAF1levels: 4.5- (100 pg/mL Cdt) and 5.7-fold
(400 pg/mL Cdt) over control levels. In addition to lymphoid cell lines, p21CIP1/WAF1 levels were
assessed in primary human lymphocytes (HPBMCs). As shown in Figure 2A,B, exposure to 25 pg/mL
Cdt resulted in a detectable but not statistically significant increase in p21CIP1/WAF1. Significant increases
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in p21CIP1/WAF1 levels were observed in the presence of 100 and 400 pg/mL Cdt leading to 361% ± 82%
and 673% ± 185% over that observed in untreated control cells.
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Figure 2. Effect of Cdt on p21CIP1/WAF1 levels in primary human lymphocytes (HPBMCs) and
MyLa cells. HPBMC and MyLa cells were treated with 0–400 pg/mL Cdt for 16 h. The cells
were harvested, and extracts w re fractionated by SDS-PAGE and analyzed by Western blot for
the presenc of p21CIP1/WAF1. Panel (A) shows representative Western blots, and panel (B) shows
results from four experiments assessed by digital densitometry; results (intensity) are expressed as the
mean± SEM. Panel (C) shows the effect of 50 pg/mL of Cdt containing wild-type CdtB (CdtBWT) or CdtB
containing mutations (CdtBR117A, CdtBR144A, and CdtBA163R) on p21CIP1/WAF1 levels in MyLa cells.
A representative Western blot is shown, as well as results from four experiments that were analyzed by
digital densitometry; results are expressed as a percentage of p21CIP1/WAF1 levels observed in control
(untreated) cells; * indicates statistical significance (p < 0.05) when compared to untreated cells.
As noted earlier, we previou ly demo str ted that Cdt toxicity in lymphocytes (bo h primary and
cell lines), macrophages, and mast cells is dependent upon PIP3 phosphatase activity exhibited by the
active C t subunit, CdtB [24–28]. We ge erated and previously reported on the characterization of
the enzymatic and toxic activities of Cdts containing targeted mutations within the CdtB subunit [24].
In each instance, we observed that the retention of lipid phosphatase activity, and not DNase activity,
was a requisite for both Cdt-induced cell-cycle arrest and apoptosis in lymphocytes, as well as
the induction of pro-inflammatory responses in macrophages. Therefore, we next determined the
requirement for PIP3 phosphatase activity in Cdt-induced increases in the levels of p21CIP1/WAF1. Cdt
containing CdtB mutant proteins that were previously described were employed [24]: CdtBA163R
retains lipid phosphatase activity, lacks DNase activity, and is toxic; CdtBR144A exhibits low lipid
phosphatase activity, exhibits increased DNase activity and is not toxic; CdtBR117A exhibits low lipid
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phosphatase activity, retains DNase activity, and is not toxic. As shown in Figure 2C, elevations in
p21CIP1/WAF1 levels were only observed when MyLa cells were treated with toxin containing the active
wild-type subunit, CdtBWT (2.5-fold increase), or the CdtB mutant, CdtBA163R (3.2-fold increase) [24].
Cells exposed to CdtB mutant proteins that we previously demonstrated to be deficient in phosphatase
activity and lack toxicity (CdtBR144A and CdtBR117A) did not exhibit significant changes in levels of
p21CIP1/WAF1: 1.2-fold and 1.7 fold, respectively. It is noteworthy that we previously reported that
A. actinomycetemcomitans Cdt-induced cell-cycle arrest and apoptosis in human lymphocytes does not
involve activation of the DNA damage response (DDR) [24,39]. These observations were confirmed as
we now demonstrate that Cdt containing CdtBWT, as well as the other CdtB mutant proteins employed
in this study, does not induce phosphorylation of the histone H2AX, a commonly employed indicator
of DDR activation due to DNA damage (Figure S1, Supplementary Materials).
The biologic activity of p21CIP1/WAF1 is governed by post-translational modifications such as
phosphorylation; therefore, we also assessed Cdt-treated Jurkat cells for changes in phosphorylation
status (T145; (pp21CIP1/WAF1)) (Figure 1C). Baseline levels of p21CIP1/WAF1 were very low, but detectable;
as described above, these levels increased at 8–16 h in the presence of Cdt (see above). In contrast,
the relative amount present as phosphorylated p21CIP1/WAF1 (pp21CIP1/WAF1) significantly declined in
the presence of Cdt. Cells treated with 50 pg/mL Cdt for 16 h exhibited a reduction in the amount of
pp21CIP1/WAF1 to 20.6%± 3.4% of the amount observed in untreated control cells. Interestingly, the PI-3K
signaling pathway exhibits cross-talk with other regulatory pathways; specifically, p21CIP1/WAF1 was
shown to be a downstream target of activated Akt (pAkt) [40]. Furthermore, we showed that
Cdt-treated cells exhibit reduced levels of pAkt (reduced kinase activity) [24]. These observations,
along with our current findings that toxin-treated cells also exhibit reduced levels of pp21CIP1/WAF1, are
consistent with the proposed molecular mode of action for CdtB which involves PIP3 phosphatase
activity leading to PI-3K signaling blockade. To further support our findings and provide additional
“proof-of-principle” evidence for a relationship between pAkt and p21CIP1/WAF1, we employed GSK690693,
an Akt inhibitor [41]. Jurkat cells treated for 16 h with 0.5 µM GSK690693, exhibited a reduction in
pp21CIP1/WAF1 to 0.7% ± 0.3% of that observed with untreated cells (Figure 1C).
2.2. Blockade of Cdt-Induced Increases in p21CIP1/WAF1 Results in Reduced Jurkat Cell Susceptibility to
Cdt Toxicity
We next extended our investigation to address the biological significance of Cdt-induced increases
in p21CIP1/WAF1 by utilizing a two-pronged approach: pharmacologic modulation and altered expression
using gene editing. The novel inhibitor of p21CIP1/WAF1, UC2288, was demonstrated to reduce
p21CIP1/WAF1 levels [42]; therefore, we firstly employed UC2288 as a potential inhibitor of Cdt toxicity
by virtue of its ability to block increases in p21CIP1/WAF1. As shown in Figure 3A, pre-treatment of
JurkatWT cells with UC2288 (2.5–10 µM) resulted in reduced Cdt-induced apoptosis in the presence
of the highest concentration of the inhibitor (10 µM); interestingly, this is the same concentration
reported to be effective in other studies [42]. Untreated control cells exhibited 7.7% ± 1.1% terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL)-positive cells and,
in the presence of 50 pg/mL Cdt, the percentage of TUNEL-positive cells increased to 35.0% ± 1.9%.
Pre-treatment of cells with UC2288 reduced the percentage of TUNEL-positive cells to 19.7% ± 1.4%.
Two inactive analogues of UC2288 were employed: UC1770 and UC1472; neither of these altered
Cdt-induced apoptosis, as the percentage of TUNEL-positive cell was not reduced below 31% when
cells were treated with equivalent concentrations of these analogues. The ability of UC2288 to block
Cdt-induced increases in p21CIP1/WAF1 levels was also confirmed (Figure 3B). Results are expressed as a
percentage of p21CIP1/WAF1 levels observed in cells exposed to toxin alone (100%); the latter represents
almost a five-fold increase over control cells (medium only). Pre-treatment with 10 µM UC2288
resulted in a significant reduction of p21CIP1/WAF1 levels to 24.7% of that observed with cells treated
with toxin alone.
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Figure 3. Effect of UC2288 on Cdt-induced apoptosis and on p21CIP1/WAF1 levels. JurkatWT cells were
pre-incubated with 0–10 µM UC2288 or its inactive analogues UC1770 and UC1472 for 30 min. Cdt
(50 pg/mL) was added to the cell cultures, and the cells were harvested 24 h later and analyzed for
apoptosis using the TUNEL assay as described (panel (A)). Results are expressed as a percentage of
apoptotic cells versus drug concentration; the mean ± SEM for four experiments is plotted. Panel (B)
shows the effect of UC2288 on Cdt-induced p21CIP1/WAF1 levels at 16 h. A representative blot is shown
along with results from four experiments. estern blots ere analyzed by digital densitometry; the
data are express d as percentage of the p21CIP1/ AF1 l vels observed in cells treated with Cdt alone;
* indicates sta istical significance (p . 5) hen compared to untr ated cells.
To confirm our observations with UC2 88 a tter understand the bi logical s gnifi ance
of Cdt-induced levations in p21CIP1/ F1 levels, we utilized CRISPR/Cas9 g ne edi ing to e tablish
a stable Jurkat cell line deficient in p21CIP1/WAF1 expression (Jurkatp21−). As shown in Figure 4A,
Jurkatp21− cells were unable to express p21CIP1/WAF1 when challenged with either Cdt or etoposide
for 16 h; in contrast, JurkatWT cells exhibited clear elevations in this protein when challenged with
either agent under identical conditions. As noted above, we established that Cdt-induced toxicity is
dependent on the CdtB subunit’s ability to function as a PIP3 phosphatase, thereby mediating blockade
of the PI-3K signaling pathway [26,27]. Therefore, we next verified that Jurkatp21− cells remained
susceptible to toxin-induced signaling blockade. Specifically, cells were assessed after 2 and 4 h of
exposure to Cdt for changes in the phosphorylation status of two downstream PI-3K signaling targets:
Akt and GSK3β. JurkatWT and Jurkatp21− cells were treated with 50 pg/mL Cdt and then analyzed by
West rn blo for the presence of Akt, pAkt, GSK3β, and pGSK3β t 0, 2, and 4 h. Figure 4B shows
representative immunoblots indicating that the levels of both pAkt and pGSK3β were reduced at
2 and 4 h in both JurkatWT and Jurkatp21−; in contrast, the total amount of these proteins (Akt and
GSK3β) remained unchanged. In previous studies, we reported that decreases in pAkt and pGSK3β
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within JurkatWT cells were statistically significant with levels of pAkt reduced to 48.7% ± 9.3% (2 h)
and 45.5% ± 11.6% (4 h) relative to untreated control cells; likewise, pGSK3β levels were reduced to
55.7% ± 6.0% and 47.6% ± 6.1% of control values at 2 and 4 h, respectively [24]. Figure 4C shows similar
compiled results from multiple experiments for Jurkatp21− cells. Akt and GSK3β levels remained
relatively constant for the 4-h period. In contrast, pAkt levels were reduced to 56.4% ± 19% (2 h) and
to 34.8% ± 16.7% (4 h); pGSK3β levels were reduced to 59.7% ± 22.7% (2 h) and 49.5% ± 21.7% (4 h).
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Figure 4. Analysis of Jurkatp21− cells. CRISPR/Cas9 gene editing was employed to produce a Jurkatp21−
cell line. Panel (A) shows the results of p21CIP1/WAF1 analysis by Western blot of both JurkatWT and
Jurkatp21− cells at 16 h following exposure to either Cdt (50 pg/mL) or etoposide (Eto; 50 µM); GAPDH
is shown as a gel loading control. Panels (B,C) show the effect of t on PI-3K signaling targets.
JurkatWT and Jurkatp21− cell re treated with medium alone (0) or with Cdt (50 pg/mL) for 2 or
4 h and the by Western blot for the expression of Akt, pAkt (S473), GSK3β, and pGSK3β
(S9), e l as actin which served s a loading control. Representative blots are show in panel (B),
and t e res lts of t ree ex eri ents for Jurkatp21− cells are show in panel (C). Data are plotted as the
percentage of protein expressed in untreated control cells; the ean ± SEM is shown and * indicates
statistical significance (p < 0.05) when compared to untreated cells. Panel (D) shows the effect of Cdt
on apoptosis (TUNEL-positive) in JurkatWT and Jurkatp21− cells. The percentage of apoptotic cells
was determined at 24 h and is plotted versus Cdt concentration; the mean ± SEM is shown for three
experiments; * indicates statistical significance (p < 0.01) when compared to untreated cells.
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JurkatWT and Jurkatp21− cells were next assessed and compared for their susceptibility to
Cdt-induced apoptosis using the TUNEL assay (Figure 4D) following a 24-h treatment with toxin.
Consistent with our previous findings, JurkatWT cells exhibit dose-dependent apoptosis; the percentages
of TUNEL-positive were 4.2% ± 0.9% (0 Cdt), 28.3% ± 1.6% (25 pg/mL Cdt), 47.7% ± 1.7% (100 pg/mL
Cdt), and 63.5% ± 0.9% (400 pg/mL Cdt). In contrast, Jurkatp21− cells were resistant to Cdt-induced
apoptosis; cells incubated with 0–400 pg/mL toxin exhibited 5.7% ± 1.7%, 8.9% ± 2.6%, 10.5% ± 3.0%,
and 12.6% ± 3.0% apoptotic cells. It is noteworthy that Jurkatp21− cells retained the capacity to undergo
apoptotic cell death as they remained sensitive to paclitaxel (Figure S2, Supplementary Materials).
Previously, we demonstrated that Cdt-induced apoptosis involves the intrinsic apoptotic pathway
and, in particular, development of the mitochondrial permeability transition (MPT) [39,43]. Therefore,
we assessed and compared JurkatWT and Jurkatp21− for expression of pro-apoptotic members of the Bcl-2
protein family in response to Cdt. Treatment of JurkatWT cells with 50 pg/mL Cdt resulted in significant
increases in both Bid and Bax at 8 hrs (Figure 5A); Bid levels increased by 498.3% ± 290.5% relative to
control cells and Bax levels increased by 637.0% ± 274.7%. A consistent, but not statistically significant,
increase was observed for Bak to 160% ± 38.0%. In comparison, Cdt failed to induce increases in the
levels of any of the three pro-apoptotic proteins in Jurkatp21− cells; relative to untreated cells, Bid, Bax,
and Bak expression levels were 73.2% ± 7.5%, 94.2% ± 10.5%, and 80.4% ± 20.4%, respectively.
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Figure 5. Effect of Cdt on the expression of pro-apoptotic Bcl-2 family members, as well as on the ∆Ψm.
Panel (A): JurkatWT and Jurkatp21− cells were incubated with medium or 50 pg/mL Cdt for 8 h. Cells
were then analyzed by Western blot for Bid, Bax, Bak, and GAPDH (loading control). Representative
blots are shown on top for Bid, Bax, Bak, and GAPDH for JurkatWT cells exposed to medium and
Cdt-treated, as well as for Jurkatp21− cells exposed to medium and Cdt-treated. Western blots were
analyzed by digital densitometry; results represent the levels of protein expressed as a percentage of
that observed in respective control cells. The mean ± SEM for five experiments is shown; * indicates
statistical significance (p < 0.05) when compared to untreated cells. Panels (B–I) show the effect of Cdt
(0–400 pg/mL) on the ∆Ψm in both JurkatWT (panels (B–E)) and Jurkatp21− cells (panels (F–I)). ∆Ψm
was determined using DIOC6(3), and the percentage of cells exhibiting a reduction the membrane
potential was determined using the analytical gate indicated; the numbers represent the mean ± SEM
of three experiments, each performed in duplicate.
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Cdt was also assessed for its ability to induce the MPT in both JurkatWT and Jurkatp21− cells by
measuring a decline in the mitochondrial transmembrane potential (∆Ψm) using the fluorochrone
DIOC6(3) [39,43]. As shown in Figure 5B–E, JurkatWT cells treated with 0–400 pg/mL Cdt exhibited a
dose-dependent increase in the percentage of cells exhibiting a decline in the ∆Ψm, with 9% in control
cells versus 34.4%, 41.5%, and 45.5% in cells exposed to 100, 200, and 400 pg/mL Cdt. In contrast,
Jurkatp21− did not exhibit a significant change in the ∆Ψm; 15.3% of control cells exhibited reduced
∆Ψm, and Cdt treatment resulted in a slight, but not statistically significant increase to 21.2%, 23.1%,
and 23% in the presence of 100, 200, and 400 pg/mL Cdt, respectively (Figure 5 F–I).
2.3. Cdt-Induced Increases in p21CIP1/WAF1 Levels and Induction of Apoptosis Are Blocked by the Chaperone HSP90
The intracellular levels of p21CIP1/WAF1 are controlled transcriptionally, as well as post-translationally,
by the proteasome. Experiments were carried out to account for the mode of Cdt-induced increases in
p21CIP1/WAF1. We firstly addressed the effect of Cdt on p21CIP1/WAF1 messenger RNA (mRNA) levels in
Jurkat cells. As shown in Figure 6A, p21CIP1/WAF1 mRNA levels were marginally elevated at high toxin
doses within 4 h and declined in the presence of the same doses of Cdt at 16 h; however, these changes
were not statistically significant. It should also be noted that A. actinomycetemcomitans Cdt-induced
increases in lymphocyte p21CIP1/WAF1 levels were previously shown to be p53-independent [35]. These
findings were confirmed as we demonstrate that Cdt-induced p21CIP1/WAF1 increases were observed in
the presence of the p53 inhibitor, pifithrin-α (Figure S3, Supplementary Materials); this inhibitor also
failed to block Cdt-induced apoptosis. Similar results were observed with Molt-4 cells (data not shown).
On the post-translational side, the chaperone HSP90 was shown to stabilize p21CIP1/WAF1 and prevent its
degradation by the proteasome [44–46]. Jurkat cells were assessed for changes in the levels of HSP90 by
Western blot following 4 and 8 h of exposure to Cdt (Figure 6B,C). Untreated cells exhibited detectable
levels of HSP90 at both time points. Exposure of Jurkat cells to Cdt for 4 h resulted in 1.5- (25 pg/mL),
2.0- (100 pg/mL), and 1.9-fold (400 pg/mL) increases in HSP90 levels. Treatment with the same doses of
Cdt for 8 h resulted in increases of 1.6-, 1.5-, and 3.6- fold. The dependence of Cdt-induced increases in
HSP90 on CdtB-associated PIP3 phosphatase activity was also assessed (Figure 6D). Jurkat cells treated
with Cdt containing the active CdtB subunits CdtBWT and CdtBA163R exhibited increased HSP90 levels
of 5.1-fold and 4.6-fold over levels observed in control cells, respectively. The HSP90 levels in cells
treated with the PIP3 phosphatase-inactive CdtB units, CdtBR117A and CdtBR144A, did not change.
The relationship between HSP90 and Cdt-induced increases in p21CIP1/WAF1 levels, as well as the
induction of apoptosis, was demonstrated by employing geldanamycin (GM), an inhibitor of HSP90
ATPase activity [47]. As shown in Figure 6E, GM was assessed for its ability to inhibit HSP90 and in turn
Cdt-induced apoptosis. Jurkat cells were pre-treated with medium or GM (0–5 µM) for 1 h, followed
by the addition of medium or Cdt (50 pg/mL). Cells were assessed for apoptosis (TUNEL-positive) 24 h
later (Figure 6E). Cells treated with medium exhibited 6.2%± 1.8% TUNEL-positive cells; in comparison,
cells treated with 50 pg/mL Cdt exhibited 63.7% ± 8.8% TUNEL-positive cells. Pre-treatment of cells
with GM followed by the addition of toxin resulted in a dose-dependent reduction in apoptosis.
In the presence of 1.25, 2.5, and 5 µM GM, the percentage of TUNEL-positive cells was reduced to
21.6% ± 0.7%, 16.4% ± 1.7%, and 8.7% ± 2.3%. It should be noted that GM alone exhibited low levels of
toxicity (net 5–10% over untreated cells).
In addition to evaluating the effects of GM on Cdt-induced apoptosis, Jurkat cells were also
assessed for p21CIP1/WAF1 levels by Western blot (Figure 6F). Untreated Jurkat cells contained marginally
detectable levels of p21CIP1/WAF1; cells treated with diluent (DMSO) or GM (2.5 µM) exhibited slight
increases in p21CIP1/WAF1 to 1.2 ± 1.0 and 1.1 ± 0.98, respectively. Cells exposed to Cdt alone exhibited
a significant increase in p21CIP1/WAF1 levels to 2.4 ± 1.0; pretreatment of cells with 2.5 µM GM reduced
p21CIP1/WAF1 to near baseline levels (0.56 ± 0.19).
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Figure 6. Cdt-induced increases in p21CIP1/WAF1 and induction of apoptosis are dependent upon HSP90.
Panel (A) shows the effects of Cdt on p21CIP1/WAF1 messenger RNA (mRNA) by RT-PCR. Jurkat cells
were incubated with 50 pg/mL Cdt for 4 and 16 h. RNA extraction, complementary DNA (cDNA)
synthesis, RT-PCR, and changes in mRNA were calculated as previously described [28]. Results
are the mean of three experiments plotted as a percentage of mRNA levels observed in control cells
(time 0). Panels (B,C) show the results of experiments that assess the effect of Cdt on HSP90 levels.
Jurkat cells were treated with Cdt (0–400 pg/mL) for 4 and 8 h, and the cell extracts were assessed
by Western blot. Panel (B) shows a representative Western blot with GAPDH as a loading control.
Panel (C) shows the results of four experiments; Western blots were analyzed by digital densitometry,
and the results are plotted as the mean intensity ± SEM. Panel (D) shows Western blot analysis of
the effect of 50 pg/mL Cdt containing CdtBWT or CdtB containing mutations (CdtBR117A, CdtBR144A,
and CdtBA163R) on HSP90 levels in Jurkat cells. A representative Western blot is shown, as well as
results from three experiments that were analyzed by digital densitometry; results are expressed as the
mean intensity ± SEM; * indicates statistical significance (p < 0.05) when compared to untreated cells.
The effects of geldanamycin D (GM) on Cdt-induced apoptosis are shown in panel (E). Jurkat cells
were incubated with 0–5 µM GM for 60 min, followed by the addition of medium and 50 pg/mL Cdt,
before being analyzed for apoptosis (TUNEL assay) 24 h later. The percentage of TUNEL-positive cells
is plotted as the mean ± SEM of four experiments. Panel (F) shows the effects of GM on Cdt-induced
increases in Jurkat cell p21CIP1/WAF1 level. Jurkat cells were treated with medium or Cdt (50 pg/mL)
in the presence of DMSO (vehicle) or 2.5 µM GM for 16 h. Cells were analyzed by Western blot and
digital densitometry for the levels of p21CIP1/WAF1. A representative blot and the results from three
experiments is shown; results are plotted as the mean ± SEM of three experiments; * indicates statistical
significance (p < 0.05) when compared to untreated cells.
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3. Discussion
3.1. Functional Significance of Cdt-induced Increases in the Levels of p21CIP1/WAF1
We now report that A. actinomycetemcomitans Cdt induces intracellular increases of p21CIP1/WAF1
in human lymphocyte cell lines, as well as primary HPBMCs. These observations are consistent
with those of other investigators who also demonstrated similar increases in response to Cdt derived
from either A. actinomycetemcomitans or Haemophilus ducreyi [16,18,35,36]. P21CIP1/WAF1 increases were
observed in a murine B-cell hybridoma cell line, fibroblasts, the Hep-2 carcinoma cell line, and a
gingival squamous cell carcinoma cell line, Ca9-22. These investigators did not demonstrate the
biological significance of the observed Cdt-dependent changes in cellular levels of p21CIP1/WAF1.
As noted earlier, increases in p21CIP1/WAF1 levels are typically observed in response to cell stress
or following DNA damage. The binding of p21CIP1/WAF1 to cyclins and their CDK binding partner
(e.g., CDK1 or CDK2) results in inhibition of the kinase complex, resulting in cell-cycle arrest (reviewed
in References [29,31–33]). It is generally accepted that p21CIP1/WAF1 regulates both cell-cycle arrest, i.e.,
checkpoint activation, and apoptosis. Collectively, the actions of p21CIP1/WAF1 promote cell survival
and provide time for cells to undergo DNA repair before completing the cell cycle. However, it is
becoming increasingly clear that the role of p21CIP1/WAF1 in regulating apoptosis is more complex
than originally thought [30,48]. For example, several investigators demonstrated that pro-apoptotic
agents induce increases in p21CIP1/WAF1 and, furthermore, over-expression of p21CIP1/WAF1 enhances
apoptosis [49–52]. Likewise, cells and animals deficient in p21CIP1/WAF1 expression exhibit reduced
susceptibility to apoptotic cell death [53,54].
In the current study, we employed a combination of gene editing (CRISPR/cas9) and pharmacologic
intervention to assess the functional consequence of Cdt-induced increases in p21CIP1/WAF1. Collectively,
our observations indicate that Cdt-induced apoptosis is dependent upon increased levels of p21CIP1/WAF1.
Jurkatp21− cells failed to exhibit apoptotic death following treatment with Cdt. Nonetheless, Jurkatp21−
cells retained their susceptibility to other pro-apoptotic agents such as paclitaxel. Additionally, we
employed the novel p21CIP1/WAF1 inhibitor UC2288 whose structure is based upon sorafenib, another
inhibitor of p21CIP1/WAF1. UC2288 is a new-generation inhibitor that exhibits greater selectivity with
higher potency to attenuate p21CIP1/WAF1 levels [41,55]. Similar to our findings with Jurkatp21− cells,
JurkatWT cells treated with Cdt in the presence of 10 µM UC2288 also failed to exhibit increased levels
of p21CIP1/WAF1; moreover, the drug suppressed Cdt-induced apoptosis. It should also be noted that
the effective dose of UC2288 used in this study was identical to that employed in other studies [41,55].
Our results demonstrate a pivotal role for p21CIP1/WAF1 in Cdt-induced apoptosis (Figure 7); these
observations encompass a non-conventional role for p21CIP1/WAF1 as it proposes a pro-apoptotic function
when increases in this regulatory protein are commonly thought to, at least initially, serve a pro-survival
role. It is well established that the pleiotropic effects of p21CIP1/WAF1 are regulated by post-transcriptional
modification. For example, phosphorylation of p21CIP1/WAF1 is known to alter its function which
includes a shift in the balance between its pro- and anti-apoptotic effects [29,31,56,57]. In this regard,
p21CIP1/WAF1 was shown to serve as a downstream target for phosphorylation (pp21CIP1/WAF1 (T-145))
by pAkt, the active form of Akt [58,59]. Consistent with these findings is our observation that
Cdt-induced increases in p21CIP1/WAF1 were not only associated with the induction of apoptosis
but also accompanied by a substantial shift in the distribution of pp21CIP1/WAF1 levels relative to
untreated cells. It is noteworthy that, in addition to inducing p21CIP1/WAF1 increases, we previously
established that treatment of lymphocytes with A. actinomycetemcomitans Cdt results in blockade of
the PI-3K signaling cascade and, furthermore, Cdt toxicity is dependent upon perturbation of these
early signaling events. Cdt-mediated PI-3K blockade is the result of potent lipid phosphatase activity,
specifically PIP3 phosphatase activity, associated with the active Cdt subunit, CdtB [26]. Cells exposed
to Cdt exhibit PI-3K signaling blockade within 2 h; this is characterized by PIP3 depletion and reduced
Akt activity [24,27,28]. It is important to note that Jurkatp21− cells retained their susceptibility to
Cdt-induced PI-3K signaling blockade but were unable to undergo apoptosis due to their inability to
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produce p21CIP1/WAF1. We propose that depletion of pAkt in Cdt-treated cells limits phosphorylation
of p21CIP1/WAF1 (Figure 7); this relationship is further supported by our finding that the Akt inhibitor,
GSK690693, also depletes JurkatWT cells of pp21CIP1/WAF1. Collectively, these findings support a critical
pro-apoptotic role for non-phosphorylated p21CIP1/WAF1 in mediating Cdt-induced cell death.
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Figure 7. Overview of the proposed mechanism via which Cdt induces p21CIP1/WAF1-dependent
apoptosis. Based upon the data presented in this paper, the proposed pathway of Cdt-induced
p21CIP1/WAF1-dependent apoptosis is shown with red arrows. The dotted line shows the proposed
relationship between Akt and the putative downstream target, p21CIP1/WAF1.
Finally, the link between increased p21CIP1/WAF1 levels and the onset of apoptosis was established
in experiments in which we assessed the ability of Cdt to alter the expression of pro-apoptotic members
of the Bcl-2 family. In previous studies, we, and others, established that Cdt-induced apoptosis involves
development of the mitochondrial permeability transition state characterized by a decrease in the
transmembrane potential and an increase in production of reactive oxygen species [43,60,61]; these
events were followed by activation of the caspase cascade. Of particular relevance to our current
study were our previous findings that over-expression of Bcl-2 blocked Cdt-induced apoptosis [39].
In this context, the pro-apoptotic requirement for p21CIP1/WAF1 in Cdt-induced apoptosis is further
supported by our current observation that the toxin induces p21CIP1/WAF1-dependent upregulation
of the pro-apoptotic proteins Bid, Bax, and Bak. P21CIP1/WAF1-dependency was demonstrated by the
observation that the levels of these proteins were not altered in Cdt-treated Jurkatp21− cells. Moreover,
Jurkatp21− cells also failed to exhibit changes in the ∆Ψm as we observed with Cdt-susceptible cells.
It is noteworthy that Gogada et al. [62] demonstrated that p21CIP1/WAF1 played a critical role in
circumin-induced apoptosis by altering mitochondrial permeability, thereby facilitating the release of
cytochrome c.
3.2. Cdt Toxicity Requires HSP90-Dependent Increases in the Levels of p21CIP1/WAF1
Eukaryotic cell-cycle progression and cell survival are regulated at multiple checkpoints involving
a number of critical regulatory proteins. One such regulatory protein is p21CIP1/WAF1 which functions
as a cyclin-dependent kinase inhibitor [29]. Elevated levels of p21CIP1/WAF1 are critical to its function;
typically, p21CIP1/WAF1 is expressed at low levels under normal growth conditions as an unstable
protein with a short half-life. It is well established that p21CIP1/WAF1 can be upregulated via a
number of p53-dependent and -independent mechanisms (reviewed in Reference [31]). Likewise,
Cdt-induced p21CIP1/WAF1 increases were reported to be both p53-dependent and -independent
(reviewed in Reference [1]); these findings led others to propose that the role of p53 with respect to
Cdt is dependent upon both the specific target cell and the source of toxin. Of particular relevance to
this study, Sato et al. [35] demonstrated that A. actinomycetemcomitans Cdt-treated lymphocytes exhibit
p53-independent increases in p21CIP1/WAF1. We confirmed these observations by demonstrating that
A. actinomycetemcomitans Cdt-treated lymphocytes exhibited increases in p21CIP1/WAF1 and apoptosis
when pre-exposed to the p53 inhibitor pifithrin-α.
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Stress and/or DNA damage are known to induce increases in p21CIP1/WAF1 levels as a result
of elevated transcription, RNA stability and/or decreased proteasomal degradation (reviewed in
References [29,33]). Cdt-induced increases in p21CIP1/WAF1 were not accompanied by significant
changes in mRNA levels. These findings led us to explore the possibility that the observed increases
were instead due to protein stabilization and reduced proteasomal degradation. It is in this context that
we considered the role of the heat shock protein HSP90 in both Cdt-induced increases in p21CIP1/WAF1
and toxicity. As noted above, p21CIP1/WAF1 is typically expressed at low levels as an unstable protein
with a short half-life in normally growing cells. HSP90 is known to function as a chaperone that is
critical to stabilizing proteins involved in several cellular processes [46]. In particular, HSP90 was
shown to be recruited to p21CIP1/WAF1 where it binds via the WAF1/CIP1 stabilizing protein 39 (WISp39).
The complex of HSP90, WISp39, and p21CIP1/WAF1 was reported to stabilize and protect the cell-cycle
inhibitor from proteasomal degradation [44,45].
We extended these observations to Cdt-induced stress in lymphocytes by firstly assessing
toxin-treated Jurkat cells for changes in both WISp39 and HSP90. Jurkat cells constitutively express
WISp39, and we observed that exposure to Cdt did not result in further increases (data not shown).
In contrast, Cdt-treated cells exhibited significant increases in HSP90 levels within 4 h, prior to the
peak elevation in p21CIP1/WAF1. It should also be noted that the ability of CdtB to alter HSP90 levels,
as demonstrated for p21CIP1/WAF1, was found to be dependent upon PIP3 phosphatase activity, since
toxin-containing CdtB subunit mutants that lacked phosphatase activity were unable to induce increases
in HSP90 levels. To further investigate the relationship between HSP90, p21CIP1/WAF1, and apoptosis,
we employed the HSP90 inhibitor, GM. Specifically, our observations demonstrate that cells pre-treated
with GM prior to exposure to Cdt prevented toxin induces increases in p21CIP1/WAF1; moreover, these
cells exhibited decreased susceptibility to toxin-induced apoptosis, demonstrating a linkage between
HSP90, changes in p21CIP1/WAF1 levels, and toxicity.
4. Conclusions
In summary, this study advances our understanding of the molecular events leading to
A. actinomycetemcomitans Cdt-mediated toxicity in lymphocytes. We previously demonstrated
that Cdt toxicity is dependent upon PI-3K signaling blockade in lymphocytes, mast cells,
and macrophages [2,24–26,28,63,64]. A key to impairment of this signaling pathway is the ability of
the active Cdt subunit, CdtB, to function as a PIP3 phosphatase. Our current observations utilized
both pharmacologic and gene editing approaches to demonstrate that toxin-induced apoptosis is
also dependent upon increased levels of p21CIP1/WAF1. Furthermore, toxin-induced increases in this
critical regulatory protein are dependent upon HSP90. Moreover, the timeline for these and previous
observations suggest a sequence in which the earliest events involve: Cdt binding to membrane
cholesterol via CdtC and CdtB, internalization of CdtB, and depletion of PIP3, leading to a concomitant
decrease in pAkt (loss of activity), increased expression/activation of HSP90, increased levels of
p21CIP1/WAF1, and increased levels of pro-apoptotic Bcl-2 family proteins [28,65]. We propose that the
ability of Cdt to impair lymphocyte proliferation and promote cell death therefore compromises the
host response to Cdt-producing organisms. Our observations are of particular significance, as Cdts
are produced by not only A. actinomycetemcomtans, but also by over 30 γ- and ε- Proteobacteria [1,2].
Therefore, we further propose that the action of this putative virulence factor contributes to the
pathogenesis of a range of diseases leading to persistent infection by Cdt-producing pathogens.
Our current findings not only contribute to a greater understanding of the molecular events critical to Cdt
toxicity, but also provide avenues for developing novel approaches to attenuating the immunoinhibitory
effects of the toxin.
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5. Materials and Methods
5.1. Reagents and Antibodies
We previously reported on the construction and expression of the plasmids which contain
the cdt genes for the holotoxin (pUCAacdtABChis), as well as those constructs containing CdtB
mutations [10]. The histidine-tagged holotoxin was isolated by nickel affinity chromatography as
previously described [66]. All antibodies were obtained from commercial sources as indicated. UC2288
was provided by RH Weiss), GM was purchased from Thermofisher Scientific (Waltham, MA, USA),
and GSK690962 was purchased from Cayman Chemical (Ann Arbor, MI, USA).
5.2. Culture Conditions and CRISPR/cas9-Mediated Genome Editing
Two human lymphoid cell lines were employed in these studies: the T-cell leukemia cell line
Jurkat (E6-1) and the cutaneous T-cell lymphoma cell line, MyLa2059. Cells were maintained as
previously described [10]. JurkatWT cells were cultured in Roswell Park Memorial Institute (RPMI)
1640 supplemented with fetal bovine serum (FBS) (10%), glutamine (2 mM), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (10 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL).
MyLa2059 cells were maintained in the same medium containing 20% FBS. Human peripheral blood
mononuclear cells (HPBMCs) were prepared and incubated as described previously [67]; blood
was obtained using an Institutional Review Board-approved protocol, and all donors provided
written consent.
To generate p21CIP1/WAF1-deficient Jurkat cells (Jurkatp21−), we utilized CRISPR/cas9 technology
(Santa Cruz Biotechnology; Santa Cruz, CA, USA) as previously described [68]. Cells were transfected
(Amaxa Nucleofector system; Lonza, Basel) with a pool of three plasmids, each encoding the Cas9
nuclease and a p21CIP1/WAF1-specific 20-nt guide RNA (gRNA). Cells were co-transfected with a pool of
three plasmids each containing a homology-directed DNA repair (HDR) template; this corresponded
to sites generated by the p21CIP1/WAF1 CRISPR/cas9 knockout plasmids. HDR plasmids insert the
puromycin resistance gene that facilitates selection of stable knockout cells. Cells were firstly incubated
for a five-day period following transfection and then for an additional seven days in incubation in
puromycin (5 µg/mL). Limiting dilution of surviving cells was utilized to clone cells; clones were
expanded and assessed by Western blot analysis for both the presence of p21CIP1/WAF1 their ability
to increase p21CIP1/WAF1 levels in response to Cdt or etoposide. Clones determined to be deficient
in p21CIP1/WAF1 were then cloned a second time using limiting dilution (Figure 4A). Jurkatp21− cell
lines were maintained in medium containing puromycin (1 µg/mL); experiments were conducted in
medium without puromycin.
5.3. Assessment of Apoptosis
JurkatWT and Jurkatp21− cells were challenged with Cdt or medium (control) for 24 h, and apoptosis
was assessed by measuring DNA fragmentation (In Situ Cell Death Detection Kit; Sigma Aldrich,
St. Louis, MI, USA) [43]. Briefly, after 24 h of incubation, the cells were re-suspended in freshly
prepared 4% formaldehyde and permeabilized with 0.1% Triton X-100 for 2 min at 4 ◦C; then, they were
washed and stained with a solution containing FITC-labeled nucleotide and terminal deoxynucleotidyl
transferase (TdT). Flow cytometry was employed to measure FITC fluorescence with a laser at 488 nm
to excite the fluorochrome; fluorescence emission was measured through a 530/30-nm bandpass filter.
To measure development of the permeability phase transition, Jurkat cells were incubated
for 18 h in medium alone or containing Cdt under conditions described above. Changes in the
transmembrane potential (∆Ψm) were determined using 4 nM 3,3′-dihexyloxacarbocyanine (DIOC6(3);
Thermofisher) [39,43]. Cells were stained for 15 min (37 ◦C) with the fluorochrome and fluorescence
measured following excitation with a laser at 488 nm (250 mW), and emission was monitored through
a 530/30-nm bandpass filter; at least 10,000 cells were analyzed per sample.
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5.4. Western Blot Analysis
Cells were incubated with and without Cdt as described above; following the indicated incubation
period, cells were solubilized in 20 mM Tris-HCl buffer (pH7.5) containing 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 1% sodium deoxycholate, and a protease inhibitor cocktail (ThermoFisher Scientific;
Waltham, MA, USA). Samples (30 µg) were fractionated on 12% SDS-PAGE and then blotted onto PVDF
membranes; the membranes were blocked with BLOTTO and then incubated with one of the following
primary antibodies (Cell Signaling Technology; Danvers, MA, USA) for 18 h at 4 ◦C [12]: anti-Akt,
anti-pAkt (S473), anti-GSK3β, anti-pGSK3β (S9), or anti-GAPDH; anti-p21CIP1/WAF1, anti-pp21CIP1/WAF1,
and anti-HSP90 antibodies were also employed (Abcam; Cambridge, MA, USA). The membranes
were incubated with goat anti-rabbit immunoglobulin conjugated to horseradish peroxidase (Southern
Biotech Technology; Birmingham, AL, USA) after they were blocked and washed. The Western blots
were developed using chemiluminescence and analyzed by digital densitometry (Li-Cor Biosciences;
Lincoln, NE, USA) as previously described [25].
5.5. Statistical Analysis
The mean ± standard error of the mean was calculated for replicate experiments. Significance
was determined using a Student’s t-test using SigmaPlot Software (Systat; San Jose, CA); a p-value of
less than 0.05 was considered to be statistically significant.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/9/1/38/s1:
Figure S1: Effect of Cdt containing CdtBWT or one of the CdtB mutants on phosphorylation of H2AX; Figure S2:
Susceptibility of Jurkatp21− cells paclitaxel; Figure S3: Effect of pifithrin-α (PFT) on Cdt-induced increases in
p21CIP1/WAF1 and apoptosis.
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